Zisková marže společnosti Aerie Pharmaceuticals Inc
Jaká je hodnota metriky Zisková marže společnosti Aerie Pharmaceuticals Inc?
Hodnota metriky Zisková marže společnosti Aerie Pharmaceuticals Inc je -17.09%
Jaká je definice metriky Zisková marže?
Zisková marže (Profit margin) je procento čistého zisku z celkových tržeb.
Profit margin is calculated with the selling price (or revenue) taken as base times 100. It is the percentage of selling price that is turned into profit. Profit percentages are calculated to find the ratio of profit to cost of an investment. Profit margin is an indicator of a company's pricing strategies and how well it controls costs. Differences in competitive strategy and product mix cause the profit margin to vary among different companies. The profit margin is used mostly for internal comparisons. It is difficult to accurately compare the net profit ratio for different entities. Individual businesses' operating and financing arrangements vary so much that different entities are bound to have different levels of expenditure, so that comparison of one with another can have little meaning. A low profit margin indicates a low margin of safety: higher risk that a decline in sales will erase profits and result in a net loss, or a negative margin.
Zisková marže společností v sektoru Health Care sektor na NASDAQ ve srovnání se společností Aerie Pharmaceuticals Inc
Čemu se věnuje společnost Aerie Pharmaceuticals Inc?
Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie's first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie's second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema.
Firmy s metrikou zisková marže podobnou společnosti Aerie Pharmaceuticals Inc
- Hodnota metriky Zisková marže společnosti Pivotree je -17.16%
- Hodnota metriky Zisková marže společnosti EQT je -17.15%
- Hodnota metriky Zisková marže společnosti EQT je -17.15%
- Hodnota metriky Zisková marže společnosti Sumo Resources Plc je -17.14%
- Hodnota metriky Zisková marže společnosti VSN Inc je -17.14%
- Hodnota metriky Zisková marže společnosti Plurilock Security je -17.14%
- Hodnota metriky Zisková marže společnosti Aerie Pharmaceuticals Inc je -17.09%
- Hodnota metriky Zisková marže společnosti Salem Media Inc je -17.08%
- Hodnota metriky Zisková marže společnosti Huayi Tencent Entertainment je -17.07%
- Hodnota metriky Zisková marže společnosti Crown Resorts je -17.02%
- Hodnota metriky Zisková marže společnosti Zevia PBC je -17.02%
- Hodnota metriky Zisková marže společnosti Kisan Mouldings je -16.99%
- Hodnota metriky Zisková marže společnosti CGG je -16.98%